Nesiritide in infants and children with congestive heart failure

Pediatric Critical Care Medicine

Volumn 6, Issue 5, 2005, Pages

  Mahle, William T ^a   Cuadrado, Angel R ^a   Kirshbom, Paul M ^b   Kanter, Kirk R ^b   Simsic, Janet M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CHLOROTHIAZIDE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; MILRINONE; NESIRITIDE; VASOACTIVE AGENT;

ADOLESCENT; ARTICLE; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIURESIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID BALANCE; HEART ARRHYTHMIA; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; INFANT; NEWBORN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 24944462055     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000164634.58297.9A     Document Type: Article

References (21)

1. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412
2. Saito Y, Nakao K, Itoh H, et al: Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158: 360-368
3. Holmes SJ, Espiner EA, Richards AM, et al: Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91-96
4. Mills RM, LeJemtel TH, Horton DP, et al: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999; 34:155-162
5. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002; 287:1531-1540
6. Karkowsky A: NDA 20-920 Natecor (nesiritide): 1-100. Washington, DC, FDA, 2001
7. Marshall J, Berkenbosch JW, Russo P, et al: Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med 2004; 19:164-170
8. Wernovsky G, Wypij D, Jonas RA, et al: Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995; 92:2226-2235
9. Hoffman TM, Wernovsky G, Atz AM, et al: Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107: 996-1002
10. Lipshultz SE, Sleeper LA, Towbin JA, et al: The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348:1647-1655
11. Burger AJ, Horton DP, LeJemtel T, et al: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002; 144:1102-1108
12. Wang DJ, Dowling TC, Meadows D, et al: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110:1620-1625
13. Marcus LS, Hart D, Packer M, et al: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184-3189
14. Morita H, Nishida Y, Motochigawa H, et al: Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. Am J Physiol 1989; 256:R792-R796
15. Chen HH, Lainchbury JG, Harty GJ, et al: Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002; 105: 999-1003
16. Zhou HL, Fiscus RR: Brain natriuretic peptide (BNP) causes endothelium-independent relaxation and elevation of cyclic GMP in rat thoracic aorta. Neuropeptides 1989; 14: 161-169
17. Chatterjee K: Phosphodiesterase inhibitors: Alterations in systemic and coronary hemodynamics. Basic Res Cardiol 1989; 84(Suppl 1):213-224
18. Kikura M, Levy JH, Michelsen LG, et al: The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulrnonary bypass. Anesth Analg 1997; 85:16-22
19. Lewis DA, Gurram NR, Abraham WT, et al: Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. Am J Health Syst Pharm 2003; 60(Suppl 4):S16-S20
20. Ilbawi MN, Idriss FS, DeLeon SY, et al: Hemodynamic effects of intravenous nitroglycerin in pediatric patients after heart surgery. Circulation 1985; 72:II101-II107
21. Shah ND, Hoffman JM, Vermeulen LC, et al: Projecting future drug expenditures-2003. Am J Health Syst Pharm 2003; 60:137-149